Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527081 | 1.00 | HDAC8 (0.60) | HDAC8LMNAPKMPTPN1PTPN2 | |
| SCHEMBL3691162 | 0.85 | HDAC8 (0.58) | HDAC8LMNAPKMPTPN1MAPT | |
| SCHEMBL3691160 | 0.85 | HDAC8 (0.58) | HDAC8LMNAPKMPTPN1MAPT | |
| SCHEMBL4516247 | 0.84 | LMNA (0.49) | HDAC8LMNAPTPN1PTPN2PTPN6 | |
| SCHEMBL23099679 | 0.81 | HDAC8 (0.54) | HDAC8LMNAPKMPTPN1MEN1 | |
| SCHEMBL29715442 | 0.80 | HDAC8 (0.55) | HDAC8LMNAPKMPTPN1MEN1 | |
| SCHEMBL23092579 | 0.80 | HDAC8 (0.55) | HDAC8LMNAPKMPTPN1MEN1 | |
| SCHEMBL17474771 | 0.79 | PTPN1 (0.57) | HDAC8LMNAPTPN1PTPN2PTPN6 | |
| SCHEMBL22962110 | 0.79 | HDAC8 (0.57) | HDAC8PTPN1 | |
| SCHEMBL14183936 | 0.78 | HDAC8 (0.62) | HDAC8PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | HDAC8 31/4885LMNA 3083/4885PKM 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.